Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Company Data

Name Harrow, Inc. - 11.875% Senior Notes due 2027

Company Harrow Health, Inc. 11.875% Senior Notes due 2027

Symbol HROWM

Website http://www.harrowinc.com

Primary Exchange

NASDAQ

ISIN US4158583074

Asset Class Share

Sector Healthcare

Industry Medical - Pharmaceuticals

CEO Mark L. Baum

Market Capitalization 1 Mrd.

Country United States of America

Currency USD

Employees 0,2 T

Address , Nashville

IPO Date 2022-12-29

Dividends from 'Harrow, Inc. - 11.875% Senior Notes due 2027'

Ex-Date	Dividend per Share
15.07.2025	0,74 USD
15.04.2025	0,74 USD
15.01.2025	0,74 USD
15.10.2024	0,74 USD
15.07.2024	0,74 USD
12.04.2024	0,74 USD
11.01.2024	0,74 USD
12.10.2023	0,74 USD
13.07.2023	0,74 USD
13.04.2023	0,74 USD

Ticker Symbols

Name	Symbol
NASDAQ	HROWM

More Shares

Investors who hold Harrow, Inc. - 11.875% Senior Notes due 2027 also have the following shares in their portfolio:

NUVEEN CREDIT STRATEGIES INCME FUND SHARES OF BENEFICIAL INTEREST Fund

WELLS FARGO 17/22 FLR MTN Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog